Analysts' Actions: CLVS ENDP THC WRB

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Clovis Oncology was upgraded at Piper Jaffray to overweight from neutral. $100 price target. Company offered positive CO-1686 data at ASCO, Piper Jaffray said.

Con-way was upgraded at Bank of America to buy from underperform. $46 price target. The Freight segment is improving faster than expected, BofA said.

Citrix Systems was downgraded at Berenberg to sell. $49 price target. Legacy business could lag, Berenberg said.

Endo Health was downgraded at Cantor Fitzgerald to sell from hold. $30 price target. Expect a prolonged restructuring period, Cantor said.

Endo Health was upgraded at Leerink Swann. $48 price target. Expectations have come down, and 2013 guidance is now achievable, Leerink Swann said.

First Horizon National was downgraded at Morgan Stanley to equal weight. There is limited near-term upside as the stock has outperformed its peers since the first quarter of 2012, Morgan Stanley said. http://www.thestreet.com/story/11942921/1/sodastream-could-be-a-threat-to-big-soda.html?kval=dontmiss


Haemonetics was initiated with a market outperform rating at JMP Securities. The company's leading market position will be bolstered by M&A, and significant margin expansion is expected ahead, JMP said. Price target is $52.

Lifepoint was upgraded at Credit Suisse to outperform from neutral. Nonurban hospitals are best positioned for health care reform, Credit Suisse said.

LRR Energy was downgraded to sell at TheStreet Ratings.

Oracle was downgraded at Berenberg to sell. $28 price target. Company may lag the pace of innovation in the software sector, Berenberg said.


Realpage was downgraded to sell at TheStreet Ratings.

Tenet Healthcare was upgraded at Deutsche Bank to buy. $55 price target. Stock is attractive, following the recent pullback, Deutsche Bank said.

VMWare was downgraded at Berenberg to sell. $57 price target. Company may be left behind by new technology trends, Berenberg said.

WR Berkley was upgraded at Bank of America/Merrill Lynch to buy from neutral. $46 price target. Stock is attractive, following a 12% pullback, BofA/Merrill said.

Stock Comments / EPS Changes

Brown-Forman estimates were reduced at UBS. Lower volume and pricing increased, said UBS.

Endo Health price target and estimates were raised at UBS. Earnings estimates were increased given the announcement of an aggressive, new strategic and operating plan, said UBS. Price target goes to $41.

Health Management Associates price target was increased at UBS to $16. Positive ACA outlook, particularly relating to exchange contract negotiations, said UBS.


VeriFone price target and estimates were reduced at UBS. Legacy issues are taking longer to resolve than expected, said UBS. Price target goes to $21.

Swift estimates, target were raised at Keybanc. Shares are now seen reaching $20. Estimates were also increased, given higher seasonal demand and more favorable diesel costs, Keybanc said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.

View Comments (0)